drugset / Trial / NCT05249920

Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)

NCT05249920 ↗

Phase 3 Completed 1362 enrolled Beijing Tiantan Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a multicentre, randomized, double-blind, placebo parallel controlled, investigator-sponsored study that aims to investigate the efficacy and safety of Edaravone Dexborneol treatment in patients with acute ischemic stroke who had received early reperfusion therapy.

Timeline

Start
2022-03-18
Primary completion
2023-02-17
Completion
2023-05-19

Outcome

Missed primary endpoint

paper risk ratio 1.11, 95% confidence interval (CI) 1.00 to 1.23; P=0.05 PMID 41500725 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexborneol Small molecule 7.5 mg —
Subject Edaravone Unknown 30 mg —

Indications